U.S. and World News : Business : Alliances and Partnerships News

Reaction Biology Corporation and Key Organics Ltd Announce Drug Discovery Collaboration

Mon, 29 Aug 2005, 12:04:00 EST

Edited by Christopher Simmons

MALVERN, PA and CORNWALL, UK - August 29 (SEND2PRESS NEWSWIRE) -- Reaction Biology Corporation ("RBC") and Key Organics Ltd ("Key") today announced that they have created a Joint Venture ("JV") to engage in high throughput drug discovery.

The purpose of the JV is to identify a series of compounds with the potential of becoming new drugs with further research, and then to partner or sell the compounds to pharmaceutical companies interested in the selected targets. Key supplies diverse sets of compounds synthesized in-house using classical organic procedures optimized for primary screening of druggable targets. RBC's DiscoveryDot(TM) microarray technology reduces screening volumes to one nanoliter size, allowing large scale screening at low cost.

The companies plan to jointly select appropriate drug targets. Key will provide compounds for screening against these targets using RBC's DiscoveryDot(TM) screening technology. Key will then provide additional chemical analysis and compound synthesis, and RBC will perform additional screening and profiling. The companies will then collaborate on further development of selected compounds.


About Reaction Biology Corporation

Reaction Biology, based in Malvern, Pa., provides high throughput screening services to the biotechnology and pharmaceutical industries. The company uses a patent-pending combination of technologies to perform screening at the nanoliter scale, while preserving quality, speed and simplicity.

Combining genomics microarray printing technology and picoliter aerosol deposition, RBC has commercialized a novel technology that drives HTS to new levels of simplicity and efficiency. www.reactionbiology.com


About Key Organics Ltd.



Key Organics Limited was formed in 1986 to supply schemes of novel, benzenoid and heterocyclic chemistry to its customers under confidentially agreements. During Key's growth over the last 18 years, custom and contract synthesis and lead optimisation programmes for clients worldwide have become an increasingly important part of its business.

The Company is based at its own well-equipped multi-lab site in Camelford, Cornwall, UK. Key Organics employs Graduate and Ph.D. chemists, including medicinal chemists, with experience in a wide range of chemical techniques and technologies. Key Organics is able to supply mg to kg quantities of compounds to a high specification. www.keyorganics.ltd.uk

R E A D E R   R E S O U R C E S
» E-mail This Article    » Printer-Friendly Version
» Choose RSS News Feeds by Topic
 Subscribe in a reader

Bookmark and/or share this content with your social network:
           

» Permalink for This Article
[ http://www.send2press.com/newswire/2005-08-0829-002.shtml ]

ADDITIONAL NEWS FROM Reaction Biology Corporation

» Reaction Biology Corp. Awarded NIH SBIR Grant for Kinase Radioisotope Microarray Screening Development » Key Organics Ltd and Reaction Biology Corporation Announce New Library Screening Format » Reaction Biology Corp. Awarded NIH R01 Screening Roadmap Grant for Microarray Screening Development » Reaction Biology Corporation and Key Organics Ltd Announce Drug Discovery Collaboration » Reaction Biology Corp. Awarded Phase II SBIR Grant for Drug Discovery

» More Alliances and Partnerships News  » Top of Page  » Home

J O U R N A L I S T   R E S O U R C E S

Media Copy of Original Press Release:
  PLAIN TEXT FORMAT (UTF-8)        PDF FORMAT

» Weekly E-Mail News Summary    » RSS Feeds by Topic
» Add Our Headlines to Your Site Automatically (FREE)

Find More News Content About
Reaction Biology Corporation

Site Search:  Our WebsiteCurrent NewsNews (pre-2005)Services